Insider Transactions in Q1 2023 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,088
-1.93%
|
$46,784
$43.88 P/Share
|
|
Mar 01
2023
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,558
+36.57%
|
-
|
|
Mar 01
2023
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,484
+39.06%
|
-
|
|
Mar 01
2023
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,674
+35.24%
|
-
|
|
Mar 01
2023
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
91,036
+9.59%
|
-
|
|
Mar 01
2023
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
36,808
+26.81%
|
-
|
|
Mar 01
2023
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,673
+25.29%
|
-
|
|
Mar 01
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,938
+38.63%
|
-
|
|
Jan 05
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,330
-5.99%
|
$88,540
$38.66 P/Share
|
|
Jan 04
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,508
-11.16%
|
$92,796
$37.21 P/Share
|
|
Jan 04
2023
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,812
-9.48%
|
$67,044
$37.21 P/Share
|
|
Jan 04
2023
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
6,673
-0.86%
|
$246,901
$37.21 P/Share
|
|
Jan 04
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,692
-10.47%
|
$62,604
$37.21 P/Share
|
|
Jan 04
2023
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,427
-13.61%
|
$89,799
$37.21 P/Share
|
|
Jan 04
2023
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,574
-9.11%
|
$95,238
$37.21 P/Share
|
|
Jan 04
2023
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,138
-5.5%
|
$42,106
$37.21 P/Share
|
|
Jan 03
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
231
-1.41%
|
$7,854
$34.48 P/Share
|
|
Jan 01
2023
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+14.66%
|
-
|
|
Jan 01
2023
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+10.13%
|
-
|
|
Jan 01
2023
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+1.0%
|
-
|
|
Jan 01
2023
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+13.48%
|
-
|